Citius Oncology

Citius Oncology is a biopharmaceutical company focused on the development and commercialization of innovative targeted cancer therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology's targeted immunotherapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).